Exploring the Ability of Novel Choroidal Biomarkers in Predicting Treatment Outcomes of Polypoidal Choroidal Vasculopathy
Ophthalmic Research · 2024
DOI: 10.1159/000541572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmic Research, 2024. Verfasst von Yue Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, …. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Choroid, Angiogenesis Inhibitors, Fluorescein Angiography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The aim of this study was to explore the relationship between choroidal biomarkers and the response to anti-VEGF in PCV eyes.
Methods
We conducted a hospital-based retrospective study. We included 54 patients diagnosed with PCV who had received standard 3 monthly anti-VEGF monotherapy and had finished regular follow-ups. Choroidal thickness (CT), three-dimensional choroidal vascularity index (CVI), and the vascular density of choriocapillaris (CCVD) were measured utilizing swept-source optical coherence tomography angiography (SS-OCTA). Effective and poor responders were classified based on the changes in morphologic features. Multivariate linear regression models were performed for the outcomes to determine independent prognostic factors. Receiver operating characteristic (ROC) curves were used to compare the predictive ability of CT and CVI as biomarkers between effective and poor responders.
Results
A higher CVI at baseline was the only factor that correlated with the poor response after 3 monthly injections of anti-VEGF (p = 0.038). The greater change of central macular thickness (CMT) was significantly correlated with increased CMT (p = 0.030), decreased CT (p = 0.042), and decreased CVI (p = 0.038) at baseline. Using ROC curves, we found that the CVI value demonstrated superior predictive ability compared to the CT value, with AUC of 0.842 and the best cut-off value of 0.445.
Conclusion
A higher three-dimensional CVI using SS-OCTA is a promising biomarker to predict the poor anatomical response to anti-VEGF treatment in PCV patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Graduate School of Peking Union Medical College, Beijing, China.
- Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Zhang, Y., Wang, J., Liu, J., Song, S., Gu, X., & Yu, X. (2024). Exploring the Ability of Novel Choroidal Biomarkers in Predicting Treatment Outcomes of Polypoidal Choroidal Vasculopathy. Ophthalmic Research. https://doi.org/10.1159/000541572
Vancouver
Zhang Y, Wang J, Liu J, Song S, Gu X, Yu X. Exploring the Ability of Novel Choroidal Biomarkers in Predicting Treatment Outcomes of Polypoidal Choroidal Vasculopathy. Ophthalmic Research. 2024. doi:10.1159/000541572
BibTeX
@article{Zhang2024,
author = {Zhang, Yue and Wang, Jianing and Liu, Jing and Song, Shuang and Gu, Xiaoya and Yu, Xiaobing},
title = {Exploring the Ability of Novel Choroidal Biomarkers in Predicting Treatment Outcomes of Polypoidal Choroidal Vasculopathy},
journal = {Ophthalmic Research},
year = {2024},
doi = {10.1159/000541572}
}
EUVIMED